{"component": "clause", "props": {"groups": [{"samples": [{"hash": "8tEstWt1qqE", "uri": "/contracts/8tEstWt1qqE#collaboration-patents", "label": "Research Collaboration and License Agreement (Entera Bio Ltd.)", "score": 30.2895277207, "published": true}, {"hash": "kifIoG7kf96", "uri": "/contracts/kifIoG7kf96#collaboration-patents", "label": "Research Collaboration and License Agreement (Entera Bio Ltd.)", "score": 30.234770705, "published": true}], "snippet_links": [{"key": "own-cost", "type": "clause", "offset": [48, 56]}, {"key": "not-limited", "type": "clause", "offset": [109, 120]}, {"key": "foreign-counterparts", "type": "definition", "offset": [216, 236]}, {"key": "the-applicable", "type": "clause", "offset": [459, 473]}, {"key": "rd-term", "type": "definition", "offset": [486, 494]}, {"key": "pursuant-to-section", "type": "definition", "offset": [504, 523]}, {"key": "similar-proceedings", "type": "clause", "offset": [664, 683]}, {"key": "relating-to", "type": "definition", "offset": [684, 695]}, {"key": "other-patent-rights", "type": "clause", "offset": [1038, 1057]}, {"key": "filing-party", "type": "definition", "offset": [1201, 1213]}, {"key": "the-non", "type": "clause", "offset": [1227, 1234]}, {"key": "copies-of", "type": "definition", "offset": [1253, 1262]}, {"key": "review-and-comment", "type": "clause", "offset": [1285, 1303]}, {"key": "the-applications", "type": "clause", "offset": [1321, 1337]}, {"key": "to-provide", "type": "definition", "offset": [1488, 1498]}, {"key": "day-period", "type": "definition", "offset": [1536, 1546]}, {"key": "statement-of-intent", "type": "clause", "offset": [1628, 1647]}, {"key": "to-file", "type": "definition", "offset": [1648, 1655]}, {"key": "a-copy-of", "type": "clause", "offset": [1761, 1770]}, {"key": "patent-authority", "type": "definition", "offset": [1824, 1840]}, {"key": "reasonably-promptly", "type": "definition", "offset": [1901, 1920]}, {"key": "notice-of", "type": "clause", "offset": [2064, 2073]}, {"key": "filing-date", "type": "definition", "offset": [2078, 2089]}, {"key": "application-number", "type": "clause", "offset": [2094, 2112]}, {"key": "status-of", "type": "clause", "offset": [2177, 2186]}, {"key": "material-communications", "type": "clause", "offset": [2191, 2214]}, {"key": "the-collaboration", "type": "clause", "offset": [2276, 2293]}, {"key": "filings-and-submissions", "type": "clause", "offset": [2426, 2449]}, {"key": "judicial-body", "type": "definition", "offset": [2497, 2510]}, {"key": "in-good-faith", "type": "definition", "offset": [2543, 2556]}, {"key": "with-respect-to", "type": "clause", "offset": [2668, 2683]}, {"key": "materials-provided", "type": "clause", "offset": [2705, 2723]}, {"key": "section-823", "type": "clause", "offset": [2759, 2772]}, {"key": "right-to", "type": "definition", "offset": [2805, 2813]}, {"key": "in-the-event", "type": "clause", "offset": [2995, 3007]}, {"key": "either-party", "type": "definition", "offset": [3008, 3020]}, {"key": "declines-to", "type": "clause", "offset": [3021, 3032]}, {"key": "the-foregoing", "type": "definition", "offset": [3068, 3081]}, {"key": "each-case", "type": "definition", "offset": [3199, 3208]}, {"key": "to-the-extent", "type": "clause", "offset": [3209, 3222]}, {"key": "contained-in", "type": "definition", "offset": [3223, 3235]}, {"key": "patent-office", "type": "definition", "offset": [3304, 3317]}, {"key": "such-party", "type": "clause", "offset": [3385, 3395]}, {"key": "other-party", "type": "definition", "offset": [3414, 3425]}, {"key": "with-reasonable-notice", "type": "clause", "offset": [3426, 3448]}, {"key": "abandoning-party", "type": "definition", "offset": [3490, 3506]}, {"key": "abandoned-patent-rights", "type": "definition", "offset": [3561, 3584]}, {"key": "necessary-action", "type": "definition", "offset": [3601, 3617]}, {"key": "prior-to-the", "type": "clause", "offset": [3692, 3704]}, {"key": "any-action", "type": "definition", "offset": [3723, 3733]}, {"key": "the-us", "type": "clause", "offset": [3801, 3808]}, {"key": "trademark-office", "type": "definition", "offset": [3819, 3835]}, {"key": "control-of-the", "type": "clause", "offset": [3947, 3961]}, {"key": "maintenance-of", "type": "clause", "offset": [3985, 3999]}, {"key": "to-transfer", "type": "clause", "offset": [4097, 4108]}, {"key": "responsibility-for", "type": "clause", "offset": [4113, 4131]}, {"key": "prosecution-and-maintenance", "type": "clause", "offset": [4145, 4172]}, {"key": "patent-counsel", "type": "definition", "offset": [4208, 4222]}, {"key": "reasonable-request", "type": "definition", "offset": [4349, 4367]}], "snippet": "EnteraBio will be primarily responsible, at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all Patent Rights constituting Collaboration Patents that: (i) solely claim Improvements to the EnteraBio Platform; or (ii) solely claim Collaboration Know-How generated solely by EnteraBio after the applicable Preclinical R&D Term or (iii) pursuant to Section 8.1.2 are owned solely by EnteraBio (the \u201cEnteraBio Prosecuted Collaboration Patents\u201d), and conducting any interferences and oppositions or similar proceedings relating to such Patent Rights. Other than the EnteraBio Prosecuted Collaboration Patents, Amgen will be primarily responsible, at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all other Patent Rights constituting Collaboration Patents and conducting any interferences and oppositions or similar proceedings relating to such Patent Rights. The filing Party will provide the non-filing Party with copies of and an opportunity to review and comment upon the text of the applications relating to the applicable Collaboration Patents at least thirty (30) days before filing; provided, however, that if it is not reasonably practicable to provide such application in such thirty (30) day period, then the filing Party will provide either a draft copy of such application or a statement of intent to file such application in such thirty (30) day period. The filing Party will provide the non-filing Party with a copy of each submission made to and document received from a patent authority, court or other tribunal regarding any Collaboration Patent reasonably promptly after making such filing or receiving such document, including a copy of each application for each Collaboration Patent as filed together with notice of its filing date and application number. The filing Party will keep the non-filing Party advised of the status of all material communications, and actual and prospective filings or submissions regarding the Collaboration Patents, and will give the non-filing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions proposed to be sent to any patent authority or judicial body. The filing Party will consider in good faith the non-filing Party\u2019s comments on such communications, filings and submissions for the Collaboration Patents. With respect to any filings or other materials provided to the non-filing Party under this Section 8.2.3, the filing Party will have the right to redact information relating to manufacturing, CMC or devices, any product other than Products or any Know-How other than Collaboration Know-How from any such filings and materials. In the event either Party declines to file, prosecute or maintain any of the foregoing Patent Rights, elects to allow any Patent Rights to lapse in any country, or elects to abandon any Patent Rights (in each case to the extent contained in the Collaboration Patents) before all appeals within the respective patent office have been exhausted (each, an \u201cAbandoned Patent Right\u201d), then: (1) such Party shall provide the other Party with reasonable notice of such decision so as to permit the non-abandoning Party to decide whether to file, prosecute or maintain such Abandoned Patent Rights and to take any necessary action (which notice shall, in any event, be given no later than sixty (60) days prior to the next deadline for any action that may be taken with respect to such Abandoned Patent Right with the U.S. Patent & Trademark Office or any foreign patent office); (2) the non-abandoning Party, at the non-abandoning Party\u2019s expense, may assume control of the filing, prosecution or maintenance of such Abandoned Patent Rights; (3) the non-abandoning Party shall have the right, at its expense, to transfer the responsibility for such filing, prosecution and maintenance of such Abandoned Patent Rights to patent counsel (outside or internal) selected by the non-abandoning Party; and (4) the abandoning Party shall, at the non-abandoning Party\u2019s reasonable request and at the non-abandoning Party\u2019s expense, assist and cooperate in the filing, prosecution and maintenance of such Abandoned Patent Rights.", "size": 5, "hash": "6c26fdc70798011480dd4a4a74224885", "id": 2}, {"samples": [{"hash": "8OsEirq2wOb", "uri": "/contracts/8OsEirq2wOb#collaboration-patents", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 26.1745379877, "published": true}, {"hash": "bf5vawBVhxf", "uri": "/contracts/bf5vawBVhxf#collaboration-patents", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 24.5975359343, "published": true}], "snippet_links": [{"key": "responsible-for", "type": "clause", "offset": [22, 37]}, {"key": "the-collaboration", "type": "clause", "offset": [206, 223]}, {"key": "promptly-provide", "type": "clause", "offset": [242, 258]}, {"key": "copies-of-material", "type": "clause", "offset": [277, 295]}, {"key": "in-addition", "type": "clause", "offset": [373, 384]}, {"key": "material-filings", "type": "clause", "offset": [459, 475]}, {"key": "with-respect-to", "type": "clause", "offset": [522, 537]}, {"key": "review-and-comment", "type": "clause", "offset": [582, 600]}, {"key": "prior-to-the", "type": "clause", "offset": [601, 613]}, {"key": "submission-of", "type": "clause", "offset": [614, 627]}, {"key": "proposed-filings", "type": "clause", "offset": [633, 649]}, {"key": "provided-that", "type": "clause", "offset": [812, 825]}, {"key": "period-of-time", "type": "clause", "offset": [1003, 1017]}, {"key": "in-case-of-disagreement", "type": "clause", "offset": [1117, 1140]}, {"key": "between-the-parties", "type": "clause", "offset": [1141, 1160]}, {"key": "maintenance-of", "type": "clause", "offset": [1205, 1219]}, {"key": "final-decision", "type": "definition", "offset": [1252, 1266]}, {"key": "subject-to", "type": "definition", "offset": [1294, 1304]}, {"key": "in-writing", "type": "clause", "offset": [1368, 1378]}, {"key": "days-prior", "type": "definition", "offset": [1529, 1539]}, {"key": "payment-due-date", "type": "definition", "offset": [1557, 1573]}, {"key": "in-order-to", "type": "clause", "offset": [1618, 1629]}, {"key": "loss-of-rights", "type": "clause", "offset": [1636, 1650]}, {"key": "in-connection-with", "type": "clause", "offset": [1652, 1670]}, {"key": "own-costs", "type": "clause", "offset": [1945, 1954]}], "snippet": "(i) Astellas shall be responsible for filing, prosecuting and maintaining any Collaboration Patents, [*]. Astellas shall consult with Cytokinetics and keep Cytokinetics reasonably informed of the status of the Collaboration Patents and shall promptly provide Cytokinetics with copies of material correspondence received from any patent authorities in connection therewith. In addition, Astellas shall promptly provide Cytokinetics with drafts of all proposed material filings and correspondences to any patent authorities with respect to the Collaboration Patents for Cytokinetics\u2019 review and comment prior to the submission of such proposed filings and correspondences. Astellas shall confer with Cytokinetics and reasonably consider Cytokinetics\u2019 comments prior to submitting such filings and correspondences, provided that Cytokinetics shall provide such comments within [*] days of receiving the draft filings and correspondences from Astellas. If Cytokinetics does not provide comments within such period of time, then Cytokinetics shall be deemed to have no comment to such proposed filings or correspondences. In case of disagreement between the Parties with respect to the filing, prosecution and maintenance of such Collaboration Patents, the final decision shall be made by Astellas, subject to subsection (ii) below.\n(ii) Astellas shall notify Cytokinetics in writing of any decision to cease prosecution and/or maintenance of, any Collaboration Patents in any country. Astellas shall provide such notice at least [*] days prior to any filing or payment due date, or any other due date that requires action in order to avoid loss of rights, in connection with such Collaboration Patent. In such event, Astellas shall permit Cytokinetics, at its discretion and expense, to continue prosecution or maintenance of such Collaboration Patent in such country, and for as long as Cytokinetics assumes such prosecution and maintenance at its own costs, such Collaboration Patent shall be [*].", "size": 8, "hash": "4be2372381c655057b49340168de027c", "id": 1}, {"samples": [{"hash": "crYtqw5RzvH", "uri": "/contracts/crYtqw5RzvH#collaboration-patents", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.8377823409, "published": true}, {"hash": "5yZvX1PfPtl", "uri": "/contracts/5yZvX1PfPtl#collaboration-patents", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.8158795346, "published": true}, {"hash": "j2hfPCln3nF", "uri": "/contracts/j2hfPCln3nF#collaboration-patents", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.6899383984, "published": true}], "snippet_links": [{"key": "each-party", "type": "clause", "offset": [0, 10]}, {"key": "responsible-for", "type": "clause", "offset": [20, 35]}, {"key": "associated-with", "type": "definition", "offset": [42, 57]}, {"key": "patent-costs", "type": "clause", "offset": [179, 191]}, {"key": "prosecution-and-maintenance-of-patents", "type": "clause", "offset": [212, 250]}, {"key": "jointly-owned", "type": "clause", "offset": [258, 271]}, {"key": "the-parties", "type": "definition", "offset": [302, 313]}], "snippet": "Each Party shall be responsible for costs associated with the Prosecution and Maintenance of any Collaboration Patents that it owns solely. Anacor and GSK shall share equally the Patent Costs associated with the Prosecution and Maintenance of Patents in the jointly owned Collaboration Patents, unless the Parties otherwise agree.", "size": 4, "hash": "e8052bfa97da85664456553a79da1647", "id": 3}, {"samples": [{"hash": "crYtqw5RzvH", "uri": "/contracts/crYtqw5RzvH#collaboration-patents", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.8377823409, "published": true}, {"hash": "5yZvX1PfPtl", "uri": "/contracts/5yZvX1PfPtl#collaboration-patents", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.8158795346, "published": true}, {"hash": "j2hfPCln3nF", "uri": "/contracts/j2hfPCln3nF#collaboration-patents", "label": "Research and Development Collaboration, Option and License Agreement (Anacor Pharmaceuticals Inc)", "score": 21.6899383984, "published": true}], "snippet_links": [{"key": "maintenance-of", "type": "clause", "offset": [52, 66]}, {"key": "by-gsk", "type": "clause", "offset": [118, 124]}, {"key": "the-parties-shall", "type": "clause", "offset": [137, 154]}, {"key": "prosecute-and-maintain", "type": "definition", "offset": [180, 202]}, {"key": "patent-applications", "type": "definition", "offset": [203, 222]}, {"key": "the-collaboration", "type": "clause", "offset": [235, 252]}, {"key": "scope-of-protection", "type": "clause", "offset": [299, 318]}, {"key": "subject-matter", "type": "clause", "offset": [328, 342]}, {"key": "rights-of", "type": "definition", "offset": [361, 370]}, {"key": "in-the-event-of", "type": "definition", "offset": [419, 434]}, {"key": "existing-third-party-rights", "type": "definition", "offset": [522, 549]}, {"key": "section-86", "type": "clause", "offset": [567, 578]}, {"key": "the-final", "type": "clause", "offset": [598, 607]}, {"key": "with-respect-to", "type": "clause", "offset": [612, 627]}, {"key": "prior-to", "type": "definition", "offset": [643, 651]}, {"key": "exercise-of", "type": "clause", "offset": [658, 669]}, {"key": "termination-of-development", "type": "clause", "offset": [739, 765]}, {"key": "collaboration-compound", "type": "definition", "offset": [861, 883]}, {"key": "neither-party", "type": "definition", "offset": [946, 959]}, {"key": "number-of", "type": "clause", "offset": [1043, 1052]}, {"key": "requests-for", "type": "clause", "offset": [1107, 1119]}, {"key": "other-party", "type": "definition", "offset": [1152, 1163]}, {"key": "the-decision", "type": "clause", "offset": [1249, 1261]}, {"key": "one-party", "type": "definition", "offset": [1265, 1274]}, {"key": "loss-of", "type": "definition", "offset": [1291, 1298]}, {"key": "right-to-file", "type": "clause", "offset": [1317, 1330]}, {"key": "continuation-application", "type": "clause", "offset": [1333, 1357]}, {"key": "request-for", "type": "clause", "offset": [1389, 1400]}, {"key": "presented-to", "type": "definition", "offset": [1480, 1492]}], "snippet": "The responsibility and strategy for Prosecution and Maintenance of any Collaboration Patents shall be mutually agreed by GSK and Anacor. The Parties shall cooperate to prepare and Prosecute and Maintain patent applications included in the Collaboration Patents in a manner that ensures a reasonable scope of protection for such subject matter and preserves the rights of each collaborator in the Collaboration Patents. In the event of any dispute regarding the Prosecution and Maintenance of any Collaboration Patents and existing Third Party rights identified under Section 8.6, Anacor shall have the final say with respect to decisions made prior to GSK's exercise of its Option with respect to such Collaboration Patents or after GSK's termination of Development, and GSK shall have final say after such exercise, with respect to those claims that cover any Collaboration Compound as to which GSK exercises its Option; provided, however, that neither Party can make a \"final say\" in any Prosecution or Maintenance matter that decreases the number of continuation applications, divisional applications or requests for continuing examination that the other Party (or any Third Party) can Prosecute and Maintain within the Collaboration Patents. If the decision of one Party would result in loss of the other Party's right to file a continuation application, a divisional application or a request for continuing examination within in the Collaboration Patents, the matter will be presented to the JPS for resolution.", "size": 4, "hash": "56f9184c3f6cabc59a5cc34c5418ba47", "id": 4}, {"samples": [{"hash": "2022DYIeiMZ", "uri": "/contracts/2022DYIeiMZ#collaboration-patents", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 22.492128679, "published": true}, {"hash": "aHjNj9t8Ixk", "uri": "/contracts/aHjNj9t8Ixk#collaboration-patents", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 22.3579739904, "published": true}], "snippet_links": [{"key": "first-right", "type": "clause", "offset": [27, 38]}, {"key": "outside-legal-counsel", "type": "definition", "offset": [58, 79]}, {"key": "by-biogen-idec", "type": "clause", "offset": [89, 103]}, {"key": "subject-to-approval", "type": "clause", "offset": [105, 124]}, {"key": "the-world", "type": "definition", "offset": [265, 274]}, {"key": "copies-of-all-correspondence", "type": "clause", "offset": [328, 356]}, {"key": "relating-to", "type": "definition", "offset": [438, 449]}, {"key": "substantive-matters", "type": "clause", "offset": [603, 622]}, {"key": "associated-with", "type": "definition", "offset": [623, 638]}, {"key": "reasonable-efforts", "type": "definition", "offset": [664, 682]}, {"key": "respond-to", "type": "definition", "offset": [740, 750]}, {"key": "from-time-to-time", "type": "clause", "offset": [788, 805]}, {"key": "in-respect-of", "type": "clause", "offset": [812, 825]}, {"key": "certain-confidential-information", "type": "clause", "offset": [1061, 1093]}, {"key": "contained-in", "type": "definition", "offset": [1094, 1106]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [1156, 1194]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [1195, 1211]}, {"key": "securities-exchange-act-of-1934", "type": "clause", "offset": [1225, 1256]}, {"key": "as-amended", "type": "definition", "offset": [1258, 1268]}, {"key": "currently-in", "type": "definition", "offset": [1312, 1324]}], "snippet": "Biogen Idec shall have the first right, using in-house or outside legal counsel selected by Biogen Idec, subject to approval, not to be unreasonably withheld by Sunesis, to prepare, file, prosecute maintain and obtain extensions of Collaboration Patents throughout the world. Biogen Idec shall: (a) ensure that Sunesis receives copies of all correspondence between Biogen Idec and/or outside legal counsel and/or any governmental offices relating to such preparation, filing, prosecution, maintenance, and obtaining of extensions, of Collaboration Patents, (b) timely consult with Sunesis regarding all substantive matters associated with such activities, (c) use reasonable efforts to periodically advise Sunesis on such activities and to respond to any reasonable inquiries Sunesis may from time to time raise in respect of such activities, and (d) not substantially negatively impact Sunesis\u2019 rights under the such Collaboration Patents. As used herein, \u201cprosecution\u201d shall include interferences, re-examinations, reissues, oppositions and the like. { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION \u201c[RESERVED]\u201d IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.", "size": 4, "hash": "061b60e0289c99847295fc337a5e5bba", "id": 5}, {"samples": [{"hash": "jvfS69kfJn9", "uri": "/contracts/jvfS69kfJn9#collaboration-patents", "label": "Collaboration Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "giSqvHY3mFf", "uri": "/contracts/giSqvHY3mFf#collaboration-patents", "label": "Collaboration Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "1Yba19AtI2u", "uri": "/contracts/1Yba19AtI2u#collaboration-patents", "label": "Collaboration Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "responsibility-for", "type": "clause", "offset": [4, 22]}, {"key": "maintenance-of", "type": "clause", "offset": [64, 78]}, {"key": "patent-committee", "type": "definition", "offset": [132, 148]}, {"key": "comprised-of", "type": "clause", "offset": [149, 161]}, {"key": "the-patent", "type": "definition", "offset": [276, 286]}, {"key": "committee-shall", "type": "definition", "offset": [287, 302]}, {"key": "telephone-calls", "type": "definition", "offset": [375, 390]}, {"key": "by-the-parties", "type": "clause", "offset": [468, 482]}, {"key": "each-party", "type": "clause", "offset": [484, 494]}, {"key": "own-costs", "type": "clause", "offset": [509, 518]}, {"key": "committee-meetings", "type": "definition", "offset": [539, 557]}, {"key": "reports-to", "type": "definition", "offset": [594, 604]}, {"key": "basis-of", "type": "clause", "offset": [630, 638]}, {"key": "the-collaboration", "type": "clause", "offset": [653, 670]}, {"key": "either-party", "type": "definition", "offset": [680, 692]}, {"key": "of-the-parties", "type": "clause", "offset": [743, 757]}, {"key": "article-12", "type": "definition", "offset": [803, 813]}, {"key": "supervision-and-direction", "type": "definition", "offset": [877, 902]}, {"key": "covered-by", "type": "definition", "offset": [934, 944]}, {"key": "filing-and-prosecution", "type": "clause", "offset": [976, 998]}, {"key": "patent-applications", "type": "definition", "offset": [1006, 1025]}, {"key": "responsibility-of", "type": "clause", "offset": [1071, 1088]}, {"key": "in-the-united-states", "type": "clause", "offset": [1096, 1116]}, {"key": "the-parties-shall", "type": "clause", "offset": [1186, 1203]}, {"key": "costs-of", "type": "clause", "offset": [1229, 1237]}, {"key": "expenses-of", "type": "clause", "offset": [1360, 1371]}], "snippet": "The responsibility for the preparation, filing, prosecution and maintenance of Collaboration Patents will be administered through a Patent Committee comprised of two (2) members: one (1) appointed by Signal and one (1) appointed by Nippon Kayaku. The Parties intend that:\n(i) The Patent Committee shall meet together at such site and timing or conduct discussion by means of telephone calls, by letter, by telefax or by E-mail at such site and means, as may be agreed by the Parties. Each Party shall pay its own costs in attending Patent Committee meetings. The Patent Committee shall provide reports to the RMC on a semi-annual basis of the status of the Collaboration Patents. Either Party may refer any dispute to the appropriate officers of the Parties for consideration and resolution pursuant to Article 12;\n(ii) Unless otherwise determined by the Patent Committee, the supervision and direction of patenting of all inventions covered by the Collaboration Patents, and filing and prosecution of all patent applications covering Collaboration Patents, shall be the responsibility of Signal in the United States and shall be the responsibility of Nippon Kayaku in Japan; and\n(iii) The Parties shall share equally the Patent Costs of preparing, filing, prosecuting and maintaining the Collaboration Patents and shall each bear their own internal costs and expenses of filing, prosecuting and maintaining the Collaboration Patents.", "size": 3, "hash": "08456e32b6b1ab7898476a7423cc905f", "id": 6}, {"samples": [{"hash": "eR8xC5vG9Nk", "uri": "/contracts/eR8xC5vG9Nk#collaboration-patents", "label": "License and Research Collaboration Agreement", "score": 27.9265556789, "published": true}, {"hash": "2x6wlB31g5q", "uri": "/contracts/2x6wlB31g5q#collaboration-patents", "label": "License and Research Collaboration Agreement (Genelabs Technologies Inc /Ca)", "score": 18.0, "published": true}], "snippet_links": [{"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [0, 33]}, {"key": "maintenance-of", "type": "clause", "offset": [76, 90]}, {"key": "section-733", "type": "clause", "offset": [139, 152]}], "snippet": "During the term of this Agreement, all preparation, filing, prosecution and maintenance of Collaboration Patents shall be governed by this Section 7.3.3.", "size": 3, "hash": "dfdaa3f447a085892801607677e6853e", "id": 7}, {"samples": [{"hash": "7zCVpelPIQz", "uri": "/contracts/7zCVpelPIQz#collaboration-patents", "label": "License Agreement (Ribogene Inc / Ca/)", "score": 18.0, "published": true}, {"hash": "6kwnZ72cU50", "uri": "/contracts/6kwnZ72cU50#collaboration-patents", "label": "License Agreement (Ribogene Inc / Ca/)", "score": 18.0, "published": true}], "snippet_links": [{"key": "collaboration-patent", "type": "definition", "offset": [9, 29]}, {"key": "in-the-territory", "type": "clause", "offset": [43, 59]}, {"key": "the-right", "type": "clause", "offset": [82, 91]}, {"key": "the-obligation", "type": "clause", "offset": [101, 115]}, {"key": "action-against", "type": "clause", "offset": [162, 176]}, {"key": "person-or-entity", "type": "definition", "offset": [181, 197]}], "snippet": "(i) If a Collaboration Patent is infringed in the Territory, Dainippon shall have the right, but not the obligation, to bring, at its own expense, an appropriate action against any person or entity directly or contributorily infringing such Collaboration Patent. In such event, RiboGene shall cooperate reasonably with Dainippon in any such action, including if", "size": 2, "hash": "8be315c138bcea72a7e2a5dfec2af1be", "id": 8}, {"samples": [{"hash": "2BHZqArWLuu", "uri": "/contracts/2BHZqArWLuu#collaboration-patents", "label": "Research and Development Collaboration and License Agreement (Dynavax Technologies Corp)", "score": 25.1861738535, "published": true}, {"hash": "HcNZdanwIf", "uri": "/contracts/HcNZdanwIf#collaboration-patents", "label": "Research and Development Collaboration and License Agreement (Dynavax Technologies Corp)", "score": 21.0, "published": true}], "snippet_links": [{"key": "responsible-for", "type": "clause", "offset": [15, 30]}, {"key": "patent-costs", "type": "clause", "offset": [35, 47]}, {"key": "associated-with", "type": "definition", "offset": [48, 63]}, {"key": "maintenance-of", "type": "clause", "offset": [84, 98]}, {"key": "patents-owned", "type": "definition", "offset": [113, 126]}, {"key": "by-gsk", "type": "clause", "offset": [280, 286]}], "snippet": "[ * ] shall be responsible for all Patent Costs associated with the Prosecution and Maintenance of Collaboration Patents owned solely by Dynavax. [ * ] shall be responsible for all Patent Costs associated with the Prosecution and Maintenance of Collaboration Patents owned solely by GSK or owned jointly by GSK and Dynavax.", "size": 2, "hash": "5c244132ca9afc828676845b22312084", "id": 9}, {"samples": [{"hash": "5NB8ElpIYG7", "uri": "/contracts/5NB8ElpIYG7#collaboration-patents", "label": "License Agreement (Sunesis Pharmaceuticals Inc)", "score": 22.492128679, "published": true}, {"hash": "dGZuy0DxFTb", "uri": "/contracts/dGZuy0DxFTb#collaboration-patents", "label": "License Agreement (Sunesis Pharmaceuticals Inc)", "score": 22.3579739904, "published": true}], "snippet_links": [{"key": "first-right", "type": "clause", "offset": [26, 37]}, {"key": "outside-legal-counsel", "type": "definition", "offset": [57, 78]}, {"key": "by-millennium", "type": "clause", "offset": [88, 101]}, {"key": "subject-to-approval", "type": "clause", "offset": [103, 122]}, {"key": "the-world", "type": "definition", "offset": [266, 275]}, {"key": "copies-of-all-correspondence", "type": "clause", "offset": [328, 356]}, {"key": "relating-to", "type": "definition", "offset": [429, 440]}, {"key": "substantive-matters", "type": "clause", "offset": [599, 618]}, {"key": "associated-with", "type": "definition", "offset": [619, 634]}, {"key": "reasonable-efforts", "type": "definition", "offset": [660, 678]}, {"key": "respond-to", "type": "definition", "offset": [736, 746]}, {"key": "from-time-to-time", "type": "clause", "offset": [784, 801]}, {"key": "in-respect-of", "type": "clause", "offset": [808, 821]}], "snippet": "Millennium shall have the first right, using in-house or outside legal counsel selected by Millennium, subject to approval, not to be unreasonably withheld, by Sunesis, to prepare, file, prosecute, maintain, and obtain extensions of Collaboration Patents throughout the world. Millennium shall: (a) ensure that Sunesis receives copies of all correspondence between Millennium or outside legal counsel or any governmental offices relating to such preparation, filing, prosecution, maintenance, and obtaining of extensions, of such Collaboration Patents, (b) timely consult with Sunesis regarding all substantive matters associated with such activities, (c) use reasonable efforts to periodically advise Sunesis on such activities and to respond to any reasonable inquiries Sunesis may from time to time raise in respect of such activities, and (d) not substantially negatively impact Sunesis\u2019s rights under such Collaboration Patents. As used herein, \u201cprosecution\u201d shall include interferences, re-examinations, reissues, oppositions and the like.", "size": 2, "hash": "668c06de635e706566b32d41e5f45d3c", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih5jb2xsYWJvcmF0aW9uLXBhdGVudHMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"children": [["dispute-resolution", "Dispute Resolution"], ["cooperation", "Cooperation"], ["prosecution-and-maintenance", "Prosecution and Maintenance"], ["instructions-to-outside-patent-counsel", "Instructions to Outside Patent Counsel"], ["abandonment", "Abandonment"]], "parents": [["intellectual-property", "Intellectual Property"], ["patent-prosecution", "Patent Prosecution"], ["patent-prosecution-and-maintenance", "Patent Prosecution and Maintenance"], ["prosecution-and-maintenance-of-patents", "Prosecution and Maintenance of Patents"], ["ownership-of-intellectual-property-rights", "Ownership of Intellectual Property Rights"]], "title": "Collaboration Patents", "size": 60, "id": "collaboration-patents", "related": [["joint-patent-rights", "Joint Patent Rights", "Joint Patent Rights"], ["joint-patents", "Joint Patents", "Joint Patents"], ["patent-rights", "Patent Rights", "Patent Rights"], ["licensed-patent-rights", "Licensed Patent Rights", "Licensed Patent Rights"], ["licensed-patents", "Licensed Patents", "Licensed Patents"]], "related_snippets": [], "updated": "2025-07-07T12:36:18+00:00", "also_ask": ["What mechanisms ensure joint ownership and control over collaboration patents?", "How can the clause address background IP and improvements to avoid future disputes?", "What are the best practices for allocating prosecution and enforcement responsibilities?", "Which governing law or jurisdiction offers the most favorable treatment for collaborative inventions?", "How can the clause be structured to withstand challenges to inventorship or validity in court?"], "drafting_tip": "Define ownership of collaboration patents to prevent future disputes; specify rights to use and license to clarify each party\u2019s entitlements; outline procedures for joint prosecution to ensure coordinated protection.", "explanation": "The Collaboration Patents clause defines how intellectual property rights, specifically patents, are managed when two or more parties work together on a joint project. It typically outlines ownership, rights to file for patents, and the sharing of any resulting patentable inventions created through the collaboration. For example, it may specify whether inventions are jointly owned or if one party has the right to file and maintain patents, and how licensing or revenue from such patents will be handled. This clause ensures clarity and prevents disputes over patent rights, fostering a cooperative environment while protecting each party\u2019s interests in jointly developed innovations."}, "json": true, "cursor": ""}}